AAM Statement on Biden-Harris Administration’s 100-Day Supply Chain Review

WASHINGTON DC (June 8, 2021) – The Association for Accessible Medicines (AAM) supports the Biden-Harris administration’s 100-day review of the pharmaceutical and active pharmaceutical ingredient (API) supply chains.

The Biden-Harris administration has produced a thoughtful plan to strengthen the security of the U.S. pharmaceutical supply chain that recognizes the importance of engaging with our allies and creating the incentives necessary to encourage additional production of essential medicines here in the United States, said AAM President and CEO Dan Leonard.

AAM and our member companies are ready to partner with the Biden-Harris administration to ensure that the generic supply chain, which performed exceptionally well since the onset of the COVID-19 pandemic, is further strengthened. We believe that with the right conditions and incentives in place, the United States can play a larger role in the global production of essential medicines, added Leonard.

In April 2020, AAM released a comprehensive set of recommendations on how to enhance the security of the U.S. pharmaceutical supply chain. AAM’s blueprint includes a six-element framework that lays out concrete actions to ensure that U.S. patients and the health care system have access to a secure and consistent supply of essential medicines.

 

MEDIA CONTACT:
Rachel Schwartz
202.249.7147 

 

About AAM

AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 20 percent of total drug spending. 

About the Biosimilars Council

The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available at www.biosimilarscouncil.org.

Association for Accessible Medicines

202.249.7100

Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.